ライフサイエンスコーパス: paroxysmal

1 all, all-cause mortality also was lower with paroxysmal (3.0%/year) compared with persistent (4.4%/ye

2 ; mean left atrial diameter, 43+/-5 mm) with paroxysmal (36 of 50 patients; 72%) or short-standing (<

3 trium diameter, 45+/-6 mm) with a history of paroxysmal (40/66, 61%) or persistent atrial fibrillatio

4 ulants were used less often in patients with paroxysmal (53%) and new onset (16%) AF than in patients

5 ntricular tachyarrhythmias on admission (70% paroxysmal, 9% persistent, 21% permanent).

6 esides the 15-year-old patient complained of paroxysmal abdominal pains.

7 During a seizure, paroxysmal activity is not restricted to the EZ, but may

8 t diagnosis with sinus rhythm (SR), 317 with paroxysmal AD, and 462 with persistent AF.

9 bolic event was lower in those patients with paroxysmal AF (1.49%/year), compared with persistent (1.

10 METHODS AND In 86 patients with paroxysmal AF (43 with >/=moderate OSA [apnea-hypopnea i

11 to permanent AF was common, particularly in paroxysmal AF (52%), and the likelihood of AF progressio

12 malities (cryptogenic 37% vs 45%; p=0.18) or paroxysmal AF (6% vs 10%; p=0.17) at baseline or of new

13 Compared with patients with paroxysmal AF (60% of cohort), those with persistent AF

14 which 226 (74%) were confined to symptomatic paroxysmal AF (average, 5+/-5; range, 1 to >20), whereas

15 al [CI], 1.89-3.60), 2.1-fold higher odds of paroxysmal AF (odds ratio, 2.14; 95% CI, 1.45-3.16) and,

16 fold higher odds of persistent compared with paroxysmal AF (odds ratio, 2.19; 95% CI, 1.66-2.88).

17 y AF (OR = 2.07, 95% CI 1.59-2.68), and with paroxysmal AF (OR = 1.98, 95% CI 1.44-2.74) and chronic

18 und present between fibrillation episodes in paroxysmal AF (PAF) might be detectable by complexity an

19 ex for AF patients was 0.6 +/- 0.5 mm Hg/mL (paroxysmal AF 0.51 +/- 0.4 and persistent AF 0.73 +/- 0.

20 Sensitivity analysis of 398 paroxysmal AF ablation procedures showed no incremental

21 Transformation to paroxysmal AF after initial ablation may be a step towar

22 edian age, 68 years; 37.2% female; 42.9% had paroxysmal AF and 57.1% had persistent AF), 89.3% comple

23 xt below) over 12 weeks in 134 patients with paroxysmal AF and implanted pacemakers where AF burden (

24 d at preferred sites in 10% of patients with paroxysmal AF and in 35% of patients with persistent AF.

25 g recurrences of AF in younger patients with paroxysmal AF and mild structural heart disease.

26 In comparison, control patients with paroxysmal AF and OSA who underwent PV isolation alone w

27 rate, including AF triggers in patients with paroxysmal AF and OSA.

28 increased from patients with sinus rhythm to paroxysmal AF and persistent AF, respectively.

29 g-term single procedure success rates in non-paroxysmal AF are disappointingly low for current stepwi

30 ocardiographic abnormalities and subclinical paroxysmal AF at baseline in patients with index events

31 ared with patients without AF, patients with paroxysmal AF at randomization had a higher risk of the

32 ange 0-12.8) and was higher in patients with paroxysmal AF compared with patients without a history o

33 %) developed permanent AF, preceded by 7+/-6 paroxysmal AF episodes.

34 442 (69%) males and 328 (51%) patients with paroxysmal AF equally distributed between the 2 groups.

35 Long-term recurrences (n=171) were paroxysmal AF in 48 patients (28%) and persistent AF/atr

36 biquitous 12-lead ECG to detect asymptomatic paroxysmal AF in at-risk populations (such as those with

37 a potential molecular mechanism involved in paroxysmal AF pathogenesis.

38 A total of 513 paroxysmal AF patients (age 54+/-11 years, 73% males) un

39 quency power CLOSE protocol in patients with paroxysmal AF significantly increases the global procedu

40 In ENGAGE AF-TIMI 48 trial, patients with paroxysmal AF suffered fewer thromboembolic events and d

41 y assigned 346 patients with drug-refractory paroxysmal AF to contact force-guided radiofrequency abl

42 (STOP AF) trial randomized 245 patients with paroxysmal AF to medical therapy versus cryoballoon-base

43 In patients with paroxysmal AF undergoing extended PV antrum isolation, t

44 Patients with paroxysmal AF underwent pulmonary vein isolation.

45 Drug refractory, paroxysmal AF was the most common ablation indication (c

46 HF patients with a history of AF, those with paroxysmal AF were at greater risk of HF hospitalization

47 Patients with drug-refractory paroxysmal AF were enrolled in a multicenter, randomized

48 /= 80 years, prior myocardial infarction and paroxysmal AF were independent predictors of OAC non-use

49 152 patients undergoing de novo ablation for paroxysmal AF were randomized to 2 different treatment a

50 Patients with drug-refractory, symptomatic paroxysmal AF were randomly assigned to either incomplet

51 miR-25 were lower in atria of patients with paroxysmal AF when compared with patients in sinus rhyth

52 Patients with paroxysmal AF who presented for AF ablation were randomi

53 ed in 24 patients with ICMs and a history of paroxysmal AF who simultaneously wore the AFSW with Smar

54 t study included 32 patients with documented paroxysmal AF who underwent PVI and had preprocedural la

55 f 291 hypertensive patients with symptomatic paroxysmal AF who were scheduled to undergo pulmonary ve

56 Among patients with paroxysmal AF without previous antiarrhythmic drug treat

57 n age 63.9 +/- 11.2 years, 56.5% male, 50.9% paroxysmal AF) were included (n = 54 patients/group).

58 56.9 +/- 11.8 years, 63.9% male, 69.2% with paroxysmal AF) who were arrhythmia-free at 12 months (ex

59 59.1 [10.7] years, 31.5% female, 64.6% with paroxysmal AF).

60 group 1: two events (0.87%) in patients with paroxysmal AF, 4 (2.3%) in patients with persistent AF,

61 are those with normal structural hearts and paroxysmal AF, although those with congestive heart fail

62 1385 patients [63%] were men, 946 [43%] had paroxysmal AF, and 1256 [57%] had persistent AF), the me

63 181 (65%) had no history of AF, 49 (18%) had paroxysmal AF, and 48 (17%) had permanent AF.

64 In paroxysmal AF, HFSA failed to achieve noninferiority at

65 longer AF duration, with more prevalent non-paroxysmal AF, higher CHADS2/CHA2DS2-VASc score, and ora

66 ng ablation) comprising 1643 patients (31.3% paroxysmal AF, left atrial diameter 41+/-3.1 mm) were in

67 approach generally agreed on for those with paroxysmal AF, optimal techniques for the ablation of no

68 ed monocentric study including patients with paroxysmal AF, planned for first CLOSE-guided pulmonary

69 35% and 10% of patients with persistent and paroxysmal AF, respectively.

70 AF had more comorbidities than patients with paroxysmal AF.

71 ndomization, and of these, 1,645 (30.0%) had paroxysmal AF.

72 y bypass surgery of whom 13 had a history of paroxysmal AF.

73 oved noninferior to RFA for the treatment of paroxysmal AF.

74 not significantly affected in subjects with paroxysmal AF.

75 ases inflammatory cytokines in patients with paroxysmal AF.

76 n of recurrence in patients with symptomatic paroxysmal AF.

77 AF/AT after TAVR, 30.2% had newly diagnosed paroxysmal AF/AT before the procedure.

78 nts (66+/-10 years; 116 [62%] men; 102 [54%] paroxysmal AF; CHA(2)DS(2)-VASc, 2.6+/-1.7).

79 The 76-patient cohort included 55 paroxysmal and 21 persistent atrial fibrillation patient

80 92 male patients and 45 female patients; 83 paroxysmal and 54 persistent) who underwent preablation

81 However, AF can be paroxysmal and asymptomatic, thereby making detection wi

82 role in the pathophysiology and treatment of paroxysmal and chronic patients with AF is unknown.

83 rogression from spontaneous atrial ectopy to paroxysmal and finally long-lasting AF.

84 Twenty-five patients with AF (20 paroxysmal and five persistent; 65 years +/- 7 [standard

85 Differences between paroxysmal and patients with persistent AF were compared

86 Paroxysmal and permanent atrial fibrillation (AF) are co

87 downregulated in the atria of patients with paroxysmal and persistent (chronic) AF.

88 onal cohort study of patients diagnosed with paroxysmal and persistent AF (undergoing their first cat

89 ess mortality (10-year survival in SR and in paroxysmal and persistent AF was 74 +/- 1%, 59 +/- 3%, a

90 (10-year post-surgical survival in SR and in paroxysmal and persistent AF was 82 +/- 1%, 70 +/- 4%, a

91 During follow-up, paroxysmal and persistent AF were associated with excess

92 enance of sinus rhythm in patients with both paroxysmal and persistent atrial fibrillation.

93 tomatic drug-refractory atrial fibrillation (paroxysmal and persistent) undergoing first or repeat ab

94 h historic images of 25 patients with AF (18 paroxysmal and seven persistent; 67 years +/- 10; 14 men

95 l FIRM-guided ablation procedures (n=24; 50% paroxysmal) at University of California, Los Angeles Med

96 Transformation from persistent to paroxysmal atrial fibrillation (AF) after ablation sugge

97 e of pulmonary vein (PV) antrum isolation in paroxysmal atrial fibrillation (AF) patients over more t

98 cts with symptomatic, persistent/high-burden paroxysmal atrial fibrillation (AF) were enrolled at 6 c

99 Unlike for paroxysmal atrial fibrillation (AF), pulmonary vein isol

100 c perturbations frequently antecede onset of paroxysmal atrial fibrillation (AF).

101 atrial activation as seen clinically during paroxysmal atrial fibrillation (AF).

102 stantial number of arrhythmia recurrences in paroxysmal atrial fibrillation (AF).

103 lmonary vein (PV) isolation in patients with paroxysmal atrial fibrillation (AF).

104 ein (PV) activity has been shown to maintain paroxysmal atrial fibrillation (AF).

105 patients with drug refractory, symptomatic, paroxysmal atrial fibrillation (AF).

106 observed in 70 patients (16.1%) before TAVR: paroxysmal atrial fibrillation (AF)/atrial tachycardia (

107 line within 5 years (odds ratio [OR]: 12.7), paroxysmal atrial fibrillation (OR: 5.19), subtherapeuti

108 The associations of paroxysmal atrial fibrillation (PAF) and persistent atri

109 t the hypothesis that PP1 is dysregulated in paroxysmal atrial fibrillation (PAF) at the level of its

110 Paroxysmal atrial fibrillation (PAF) detection was highe

111 heter ablation is important for treatment of paroxysmal atrial fibrillation (PAF).

112 g persistent atrial fibrillation (LPeAF), or paroxysmal atrial fibrillation (PAF); if right atrial si

113 CH Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (SMART-AF) trial using sh

114 The Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) trial randomize

115 59%) male, 47.3+/-17 years old, having vagal paroxysmal atrial fibrillation 58 (70%) or neurocardioge

116 ustained ventricular tachycardia [n=1], fast paroxysmal atrial fibrillation [n=1], symptomatic bradyc

117 Among patients with paroxysmal atrial fibrillation and hypertension, renal d

118 Patients with history of paroxysmal atrial fibrillation and indication for corona

119 blanking period after catheter ablation for paroxysmal atrial fibrillation but calls into question t

120 which patients 18 to 80 years of age who had paroxysmal atrial fibrillation for which they had not pr

121 or pulmonary vein isolation in patients with paroxysmal atrial fibrillation has demonstrated encourag

122 for ablation of drug refractory, symptomatic paroxysmal atrial fibrillation in 172 participants recru

123 However, paroxysmal atrial fibrillation is often asymptomatic and

124 ersus single tip wide area catheter ablation-paroxysmal atrial fibrillation is the first multinationa

125 for atrial fibrillation and represented with paroxysmal atrial fibrillation or atrial tachycardia und

126 Paroxysmal atrial fibrillation patients underwent PV iso

127 predict the trigger origins in patients with paroxysmal atrial fibrillation receiving catheter ablati

128 In patients with symptomatic paroxysmal atrial fibrillation that has not responded to

129 dergoing radiofrequency catheter ablation of paroxysmal atrial fibrillation to receive remote IPC or

130 A total of 401 patients with paroxysmal atrial fibrillation undergoing pulmonary vein

131 Forty patients with paroxysmal atrial fibrillation underwent mandatory repea

132 ke or TIA who were 55 years of age or older, paroxysmal atrial fibrillation was common.

133 Paroxysmal atrial fibrillation was the predominant recur

134 patients with symptomatic, drug-refractory, paroxysmal atrial fibrillation were enrolled in a prospe

135 Patients with paroxysmal atrial fibrillation were randomized to MEA (6

136 e retrospectively analyzed 521 patients with paroxysmal atrial fibrillation who underwent catheter ab

137 age 59+/-10, CHA(2)DS(2)-VASc 1.3+/-1.1, 54% paroxysmal atrial fibrillation) were allocated to the PV

138 king at least 1 antihypertensive medication, paroxysmal atrial fibrillation, and plans for ablation w

139 e treatment of patients with drug-refractory paroxysmal atrial fibrillation, and there was no signifi

140 tepwise analysis including age, male gender, paroxysmal atrial fibrillation, basal QTc values, basal

141 pain syndrome, hypertension, and refractory paroxysmal atrial fibrillation, for which she had underg

142 edical management of individuals with covert paroxysmal atrial fibrillation, is a topic of intensive

143 ad higher basal heart rates, higher rates of paroxysmal atrial fibrillation, lower platelet count.

144 ated in cryptogenic stroke, including occult paroxysmal atrial fibrillation, patent foramen ovale, ao

145 receiving initial treatment for symptomatic, paroxysmal atrial fibrillation, there was a significantl

146 Fibrillation; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was eva

147 In the enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based

148 inferiority study included 140 patients with paroxysmal atrial fibrillation, which was refractory to

149 and simple pulmonary vein isolation to treat paroxysmal atrial fibrillation.

150 er ablation as treatment for drug-refractory paroxysmal atrial fibrillation.

151 in symptomatic patients with drug-refractory paroxysmal atrial fibrillation.

152 or pulmonary vein isolation in patients with paroxysmal atrial fibrillation.

153 ssociated with postblanking AT recurrence in paroxysmal atrial fibrillation.

154 al-time CF in the treatment of patients with paroxysmal atrial fibrillation.

155 tion model for NPV triggers in patients with paroxysmal atrial fibrillation.

156 ersus RF ablation for treating patients with paroxysmal atrial fibrillation.

157 trial arrhythmia recurrence in patients with paroxysmal atrial fibrillation.

158 rillation who underwent catheter ablation of paroxysmal atrial fibrillation.

159 y and effectiveness of catheter-based PFA in paroxysmal atrial fibrillation.

160 l (VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients

161 RAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation; NCT03714178).

162 hepatic failure (3%), liver abscesses (3%), paroxysmal atrial tachycardia (3%), thoracic pain (3%),

163 Four cases of (paroxysmal) atrial fibrillation are presented, two cases

164 ominantly inherited disease characterized by paroxysmal attacks of ataxia and nystagmus.

165 Further, the paroxysmal character, nocturnal pattern, and spontaneous

166 mbination-known as infantile convulsions and paroxysmal choreoathetosis (ICCA)-are related autosomal

167 rely presents with the classical symptoms of paroxysmal cough, whooping, apnea, and cyanosis.

168 es, presence of cough >/=14 days (20.5%) and paroxysmal coughing spells (33.3%) at diagnosis were unc

169 uited to successive seizures and consecutive paroxysmal cycles within a seizure.

170 ause for a wide and yet evolving spectrum of paroxysmal diseases.

171 ss of brain disorders that usually result in paroxysmal disorders, although their role in other neuro

172 d in an autosomal dominant fashion and cause paroxysmal disturbances of neurological function, althou

173 Paroxysmal dizziness spells (PDS), a unique LGI1-IgG acc

174 , peripheral manifestations, and stereotypic paroxysmal dizziness spells are common with LGI1-IgG.

175 dysfunction is a rare disorder that leads to paroxysmal dizziness, fatigue, and syncope because of a

176 Paroxysmal dyskinesia can be subdivided into three clini

177 studies have been carried out on each of the paroxysmal dyskinesia genes, to date there has been no l

178 ns including MDs that look like seizure (eg, paroxysmal dyskinesia, status dystonicus) and seizures t

179 a dominant form of generalized epilepsy and paroxysmal dyskinesia.

180 Paroxysmal dyskinesias (PxD) refer to a rare group of cl

181 wo of PNKD) in a series of 145 families with paroxysmal dyskinesias as well as in a series of 53 pati

182 ng group of episodic movement disorders, the paroxysmal dyskinesias, and study of the causative genes

183 weeks) or late (>6 weeks after ablation) and paroxysmal (either spontaneous conversion or treated wit

184 st, independently of any stimulus and of any paroxysmal electroencephalographic activity.

185 ansition of normal physiological function to paroxysmal epileptic activity.

186 ve of 16 patients developed additional brief paroxysmal episodes in puberty, either dystonic/dyskinet

187 Seizures are paroxysmal events in which increased neuronal activity i

188 patient diary to record motor and non-motor paroxysmal events.

189 l kinesigenic dyskinesia or choreoathetosis, paroxysmal exercise-induced dyskinesia, and paroxysmal n

190 syndromes such as erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD).

191 ted with inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD).

192 Inherited "paroxysmal extreme pain disorder" (PEPD) differs in its

193 ion in which trigeminal stimulation triggers paroxysmal facial pain, affects defensive peripersonal s

194 hallenging to detect by ECG analysis when in paroxysmal form.

195 (>/=7 consecutive days of AF >/=23 hours/d), paroxysmal (>/=1 day with AF >/=6 hours), or no/little A

196 h a basal brain hyperexcitability results in paroxysmal hypersynchronous neuronal discharges.

197 to vasoconstrictive agents, thus producing a paroxysmal-hypertensive phenotype.

198 Initial recurrence was paroxysmal in 169 patients (76%) and persistent in 52 pa

199 s was 68 years, 34.4% were women, and AF was paroxysmal in 43.0%.

200 ears, the predominant arrhythmia pattern was paroxysmal in 62.3%, persistent in 28.2%, and permanent

201 Postrandomization AF/AT, which remained paroxysmal in 69.5%, did not reduce biventricular pacing

202 amilial infantile epilepsy (41.7%; n = 602), paroxysmal kinesigenic dyskinesia (38.7%; n = 560) and i

203 Paroxysmal kinesigenic dyskinesia (PKD) is characterized

204 Benign familial infantile seizures (BFIS), paroxysmal kinesigenic dyskinesia (PKD), and their combi

205 be subdivided into three clinical syndromes: paroxysmal kinesigenic dyskinesia or choreoathetosis, pa

206 x patients with 16p11.2 microdeletions and a paroxysmal kinesigenic dyskinesia phenotype have been re

207 nfantile convulsions and choreoathetosis and paroxysmal kinesigenic dyskinesia, confirming a common d

208 ssociated with variable phenotypes including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesi

209 Most atrial fibrillation was paroxysmal; less than 2% of admissions were always in at

210 e 21 105 patients were categorized as having paroxysmal (<7 days duration), persistent (>/=7 days but

211 UT1-DS experienced a mean of 30.8 (+/- 27.7) paroxysmal manifestations (52% motor events) at baseline

212 a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioener

213 After withdrawal, paroxysmal manifestations recurred with a mean of 24.2 (

214 GLUT1-DS (7-47 years old) with non-epileptic paroxysmal manifestations.

215 f 219 AF patients referred for ablation (59% paroxysmal, mean CHA2DS2VASc score 1.7 +/- 1.4) were enr

216 In addition, the nonepileptic paroxysmal movement disorder hyperekplexia has not previ

217 In patients with paroxysmal movement disorders 68 families had mutations

218 n various regions of the brain, resulting in paroxysmal movement disorders and seizure phenotypes.

219 The investigation of paroxysmal movement disorders should always include the

220 al syndromes of infancy, including epilepsy, paroxysmal movement disorders, and migraine.

221 s the phenotype-genotype overlap among these paroxysmal movement disorders.

222 Samples from 660 patients with paroxysmal (n = 370) or persistent AF (n = 290) were gen

223 ts, 61%; 64.0+/-10.0 years) with symptomatic paroxysmal (n=345; 42%) or persistent atrial fibrillatio

224 during (induced) AF in 10 patients with AF (paroxysmal: n=3; persistent: n=4; and longstanding persi

225 d interictal function are unaffected in many paroxysmal neurological channelopathies, possibly explai

226 ase, at glycine-305 was previously linked to paroxysmal neurological disorders in humans.

227 ating, hemiplegic episodes; seizures and non-paroxysmal neurological features also occur.

228 6; 95% confidence interval [CI], 1.30-2.12), paroxysmal nocturnal dyspnea (odds ratio 1.95; 95% CI, 1

229 among self-reported PE, 2-pillow orthopnea, paroxysmal nocturnal dyspnea, left and right ventricular

230 eezing, chest pain, palpitations, orthopnea, paroxysmal nocturnal dyspnea, swelling of the legs or fe

231 ablished for rare clinical disorders such as paroxysmal nocturnal haemoglobinuria and atypical haemol

232 cluding age-related macular degeneration and paroxysmal nocturnal hemoglobinurea.

233 predisposes individuals to disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical h

234 5 monoclonal antibody (mAb) for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical h

235 , has been shown to prevent complications of paroxysmal nocturnal hemoglobinuria (PNH) and improve qu

236 Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are pathogenic

237 Paroxysmal nocturnal hemoglobinuria (PNH) cells are susc

238 Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder

239 Paroxysmal nocturnal hemoglobinuria (PNH) is a nonmalign

240 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone

241 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired

242 Paroxysmal nocturnal hemoglobinuria (PNH) is characteriz

243 Paroxysmal nocturnal hemoglobinuria (PNH) is characteriz

244 vivo measurements of complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on ec

245 ate that the erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) undergoing ecu

246 The clinical management of paroxysmal nocturnal hemoglobinuria (PNH), a rare but li

247 including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemo

248 ring work on hemolytic disorders, especially paroxysmal nocturnal hemoglobinuria (PNH).

249 progenitor cells (HSPCs) from patients with paroxysmal nocturnal hemoglobinuria (PNH).

250 ctivation on erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH); the authors d

251 mAb approved for treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolyt

252 from other TMAs based on the hypothesis that paroxysmal nocturnal hemoglobinuria cells are more sensi

253 a 5-fold-enhanced complement regulation on a paroxysmal nocturnal hemoglobinuria patient's erythrocyt

254 ical trials of complement inhibitors include paroxysmal nocturnal hemoglobinuria, cold agglutinin dis

255 omide-treated erythrocytes that recapitulate paroxysmal nocturnal hemoglobinuria, PspCN enhanced prot

256 esistance in a small number of patients with paroxysmal nocturnal hemoglobinuria.

257 roliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria.

258 val = 1.06-1.13), which is intronic to PNKD (paroxysmal non-kinesigenic dyskinesia) and TMBIM1 (trans

259 including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, episodic ataxia a

260 paroxysmal exercise-induced dyskinesia, and paroxysmal non-kinesigenic dyskinesia.

261 Paroxysmal nonkinesigenic dyskinesia (PNKD) is an autoso

262 trial tissue was obtained from patients with paroxysmal or chronic AF and from control subjects in si

263 Fifty-three patients with symptomatic paroxysmal or persistent AF and without significant valv

264 ation, and oxidative stress in patients with paroxysmal or persistent AF not receiving conventional a

265 y and defibrillator implant and a history of paroxysmal or persistent AF were eligible.

266 We enrolled consecutive patients with paroxysmal or persistent AF who underwent cryoballoon pu

267 l-arm study in 337 patients with symptomatic paroxysmal or persistent AF within 6 months of enrollmen

268 In 178 patients with paroxysmal or persistent AF, LA voltage maps were create

269 statistically different whether patients had paroxysmal or persistent AF.

270 from AF/atrial tachycardia in patients with paroxysmal or persistent AF.

271 y 12 g of pure alcohol) per week and who had paroxysmal or persistent atrial fibrillation in sinus rh

272 Ten patients with symptomatic paroxysmal or persistent atrial fibrillation underwent s

273 erica and 4.5 million in European Union have paroxysmal or persistent atrial fibrillation.

274 s used with a custom mapping system to treat paroxysmal or persistent atrial fibrillation.

275 ous leiomyomas can be associated with severe paroxysmal pain in which nerve conduction may have a key

276 enetic pain disorders that range from severe paroxysmal pain to a congenital inability to sense pain.

277 ngenital heart disease, with a predominantly paroxysmal pattern.

278 nch block, Left atrium >/=47 mm, Type of AF [paroxysmal, persistent or long-standing persistent], and

279 investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2

280 Patients with a history of paroxysmal, persistent, or chronic AF, with bicuspid aor

281 n symptoms, the type of atrial fibrillation (paroxysmal, persistent, or long-standing persistent), pa

282 for scores >/=2, regardless of whether AF is paroxysmal, persistent, or permanent.

283 bodies were simultaneously tapped during the paroxysmal phase of this eruption.

284 mechanisms of ranolazine in sheep models of paroxysmal (PxAF) and persistent AF (PsAF).

285 additional 15 (10.0%) patients regressed to paroxysmal recurrences only.

286 s of all three genes, but around half of our paroxysmal series remain genetically undefined implying

287 r study indicates that detection of AF, even paroxysmal, should trigger prompt consideration for surg

288 The unifying term for the syndrome-paroxysmal sympathetic hyperactivity (PSH)-and clear dia

289 as the single causative gene for a group of paroxysmal syndromes of infancy, including epilepsy, par

290 The fast and frequent progression from paroxysmal to (long-standing) persistent or permanent AF

291 trial tachyarrhythmia and (2) progression of paroxysmal to (long-standing) persistent/permanent AF du

292 cteristics progressively worsened from SR to paroxysmal to persistent AF.

293 he mechanisms underlying the transition from paroxysmal to persistent atrial fibrillation (AF).

294 his extends the potential role of PFA beyond paroxysmal to persistent forms of AF.

295 progression of atrial fibrillation (AF) from paroxysmal to persistent forms remains a major clinical

296 tremor, tardive tremor and rabbit syndrome, paroxysmal tremors (hereditary chin tremor, bilateral hi

297 omly assigned 303 patients with symptomatic, paroxysmal, untreated atrial fibrillation to undergo cat

298 d postcontrast ventricular T1 time, AF type (paroxysmal versus persistent), AF duration, and body mas

299 Patients experiencing paroxysmal (versus persistent) initial recurrence were m

300 This association was independent of AF type (paroxysmal vs. persistent).